Efficacy and safety of coadministration of ezetimibe and simvastatin in African-American patients with primary hypercholesterolemia

Journal of the National Medical Association

Volumn 98, Issue 5, 2006, Pages 772-778

  Rodney, Roxanne A ^a   Sugimoto, Daniel ^b   Wagman, Bernard ^c   Zieve, Franklin ^d   Kerzner, Boris ^a   Strony, John ^a   Yang, Bo ^a   Suresh, Ramachandran ^a   Veltri, Enrico ^a  

^a MERCK RESEARCH LABORATORIES   (United States)

^b Cedar Crosse Research Center   (United States)

^c McGuire Research Institute ^*

^d Health Trends Research   (United States)

Author keywords

Cholesterol absorption inhibitor; LDL cholesterol; Race ethnicity; Statin

Indexed keywords

ALANINE AMINOTRANSFERASE; APOLIPOPROTEIN B; ASPARTATE AMINOTRANSFERASE; C REACTIVE PROTEIN; CREATINE KINASE; EZETIMIBE; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPID; LOW DENSITY LIPOPROTEIN CHOLESTEROL; PLACEBO; SIMVASTATIN; TRIACYLGLYCEROL;

ABSCESS; AFRICAN AMERICAN; ARTICLE; BODY MASS; CEREBROVASCULAR ACCIDENT; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERANCE; HUMAN; HYPERCHOLESTEROLEMIA; MAJOR CLINICAL STUDY; MULTICENTER STUDY; MUSCLE DISEASE; MYALGIA; NEPHELOMETRY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; SARCOIDOSIS; SINGLE BLIND PROCEDURE;

ADULT; AFRICAN AMERICANS; AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HUMANS; HYDROXYMETHYLGLUTARYL-COA REDUCTASE INHIBITORS; HYPERCHOLESTEROLEMIA; MALE; MIDDLE AGED; SAFETY; SIMVASTATIN; TREATMENT OUTCOME;

EID: 33646519444     PISSN: 00279684     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (19)

1. Heart Disease and Stroke Statistics - 2005 Update, American Heart Association. Dallas, TX.
2. Executive Summary of The Third Report of The National Cholesterol Education Program (NCEP) Expert Panel on Detection, Evaluation, And Treatment of High Blood Cholesterol In Adults (Adult Treatment Panel III). JAMA. 2001;285:2486-2497.
3. Grundy SM. Obesity, metabolic syndrome, and coronary atherosclerosis. Circulation. 2002;105:2696-2698.
4. Grundy SM, Cleeman JI, Merz CN, et al. Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III guidelines. Circulation. 2004;110:227-239.
5. Knopp RH. Drug treatment of lipid disorders. N Engl J Med. 1999;341:498-511.
6. Van Heek M, France CF, Compton DS, et al. In vivo metabolism-based discovery of a potent cholesterol absorption inhibitor, SCH58235, in the rat and rhesus monkey through the identification of the active metabolites of SCH48461. J Pharmacol Exp Ther. 1997;283:157-163.
7. Knopp RH, Dujovne CA, Le Beaut A, et al. Evaluation of the efficacy, safety, and tolerability of ezetimibe in primary hypercholesterolaemia: a pooled analysis from two controlled phase III clinical studies. Int J Clin Pract. 2003;57:363-368.
8. Kerzner B, Corbelli J, Sharp S, et al. Efficacy and safety of ezetimibe coadministered with lovastatin in primary hypercholesterolemia. Am J Cardiol. 2003;91:418-424.
9. Davidson MH, McGarry T, Bettis R, et al. Ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia. J Am Coll Cardiol. 2002;40:2125-2134.
10. Ballantyne CM, Houri J, Notarbartolo A et al. Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Circulation. 2003;107:2409-2415.
11. Melani L, Mills R, Hassman D, et al. Efficacy and safety of ezetimibe coadministered with pravastatin in patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial. Eur Heart J. 2003;24:717-728.
12. Davidson MH, Ballantyne CM, Kerzner B, et al. Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2,382 patients with primary hypercholesterolemia. Int J Clin Pract. 2004;58:746-755.
13. Friedewald WT, Levy RI, Fredrickson DS. Estimation of the concentration of low-density lipoprotein cholesterol in plasma, without use of the preparative ultracentrifuge. Clin Chem. 1972;18:499-502.
14. Sager PT, Melani L, Lipka L, et al. Effect of coadministration of ezetimibe and simvastatin on high-sensitivity C-reactive protein. Am J Cardiol. 2003;92:1414-1418.
15. Sager PT, Capece R, Lipka L, et al. Effects of ezetimibe coadministered with simvastatin on C-reactive protein in a large cohort of hypercholesterolemic patients. Atherosclerosis. 2005;179:361-367.
16. Ockene IS, Matthews CE, Rifai N, et al. Variability and classification accuracy of serial high-sensitivity C-reactive protein measurements in healthy adults. Clin Chem. 2001;47:444-450.
17. Ferdinand KC, Clark LT, Watson KE, et al. Comparison of efficacy and safety of rosuvastatin and atorvastatin in African-American patients in a six-week trial. Am J Cardiol. 2006;97:229-235.
18. Feldman T, Koren M, Insull W Jr, et al. Treatment of high-risk patients with ezetimibe plus simvastatin co-administration versus simvastatin alone to attain National Cholesterol Education Program Adult Treatment Panel III low-density lipoprotein cholesterol goals. Am J Cardiol. 2004;93:1481-1486.
19. Goldberg AC, Sapre A, Liu J, et al. Efficacy and safety of ezetimibe coadministered with simvastatin in patients with primary hypercholesterolemia: a randomized, double-blind, placebo-controlled trial. Mayo Clin Proc. 2004;79:620-629.